VERTEX PHARMACEUTICALS INC (VX1.DE) Stock Fundamental Analysis

FRA:VX1 • US92532F1003

403.3 EUR
-2.5 (-0.62%)
Last: Feb 18, 2026, 09:59 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to VX1. VX1 was compared to 78 industry peers in the Biotechnology industry. While VX1 has a great profitability rating, there are some minor concerns on its financial health. VX1 is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year VX1 was profitable.
  • VX1 had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: VX1 reported negative net income in multiple years.
  • In multiple years VX1 reported negative operating cash flow during the last 5 years.
VX1.DE Yearly Net Income VS EBIT VS OCF VS FCFVX1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

1.2 Ratios

  • With an excellent Return On Assets value of 14.78%, VX1 belongs to the best of the industry, outperforming 89.74% of the companies in the same industry.
  • VX1's Return On Equity of 21.22% is amongst the best of the industry. VX1 outperforms 93.59% of its industry peers.
  • With an excellent Return On Invested Capital value of 15.66%, VX1 belongs to the best of the industry, outperforming 93.59% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for VX1 is significantly above the industry average of 11.39%.
Industry RankSector Rank
ROA 14.78%
ROE 21.22%
ROIC 15.67%
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.53%
ROIC(5y)18.06%
VX1.DE Yearly ROA, ROE, ROICVX1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40

1.3 Margins

  • With an excellent Profit Margin value of 31.35%, VX1 belongs to the best of the industry, outperforming 87.18% of the companies in the same industry.
  • VX1 has a better Operating Margin (38.70%) than 94.87% of its industry peers.
  • In the last couple of years the Operating Margin of VX1 has grown nicely.
  • The Gross Margin of VX1 (86.28%) is better than 79.49% of its industry peers.
  • VX1's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 38.7%
PM (TTM) 31.35%
GM 86.28%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
VX1.DE Yearly Profit, Operating, Gross MarginsVX1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), VX1 is creating value.
  • There is no outstanding debt for VX1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VX1.DE Yearly Shares OutstandingVX1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
VX1.DE Yearly Total Debt VS Total AssetsVX1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

2.2 Solvency

  • There is no outstanding debt for VX1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z N/A
ROIC/WACC1.8
WACC8.68%
VX1.DE Yearly LT Debt VS Equity VS FCFVX1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

2.3 Liquidity

  • VX1 has a Current Ratio of 2.36. This indicates that VX1 is financially healthy and has no problem in meeting its short term obligations.
  • VX1's Current ratio of 2.36 is in line compared to the rest of the industry. VX1 outperforms 50.00% of its industry peers.
  • A Quick Ratio of 2.00 indicates that VX1 should not have too much problems paying its short term obligations.
  • With a Quick ratio value of 2.00, VX1 perfoms like the industry average, outperforming 46.15% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.36
Quick Ratio 2
VX1.DE Yearly Current Assets VS Current LiabilitesVX1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • VX1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 6248.28%, which is quite impressive.
  • Measured over the past years, VX1 shows a quite strong growth in Earnings Per Share. The EPS has been growing by 12.27% on average per year.
EPS 1Y (TTM)6248.28%
EPS 3Y7.33%
EPS 5Y12.27%
EPS Q2Q%26.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%9.55%

3.2 Future

  • The Earnings Per Share is expected to grow by 11.80% on average over the next years. This is quite good.
  • VX1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.15% yearly.
EPS Next Y10.74%
EPS Next 2Y11.49%
EPS Next 3Y10.83%
EPS Next 5Y11.8%
Revenue Next Year8.7%
Revenue Next 2Y9.21%
Revenue Next 3Y9.38%
Revenue Next 5Y9.15%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
VX1.DE Yearly Revenue VS EstimatesVX1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B 20B
VX1.DE Yearly EPS VS EstimatesVX1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 10 20 30 40

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 25.90, the valuation of VX1 can be described as expensive.
  • VX1's Price/Earnings ratio is rather cheap when compared to the industry. VX1 is cheaper than 83.33% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of VX1 to the average of the S&P500 Index (27.16), we can say VX1 is valued inline with the index average.
  • VX1 is valuated rather expensively with a Price/Forward Earnings ratio of 23.39.
  • Based on the Price/Forward Earnings ratio, VX1 is valued cheaply inside the industry as 84.62% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.10, VX1 is valued at the same level.
Industry RankSector Rank
PE 25.9
Fwd PE 23.39
VX1.DE Price Earnings VS Forward Price EarningsVX1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, VX1 is valued cheaply inside the industry as 80.77% of the companies are valued more expensively.
  • VX1's Price/Free Cash Flow ratio is rather cheap when compared to the industry. VX1 is cheaper than 84.62% of the companies in the same industry.
Industry RankSector Rank
P/FCF 36.26
EV/EBITDA 24.38
VX1.DE Per share dataVX1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • VX1 has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.41
PEG (5Y)2.11
EPS Next 2Y11.49%
EPS Next 3Y10.83%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for VX1!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VERTEX PHARMACEUTICALS INC

FRA:VX1 (2/18/2026, 9:59:29 AM)

403.3

-2.5 (-0.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12
Earnings (Next)05-04
Inst Owners97.56%
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap102.33B
Revenue(TTM)N/A
Net Income(TTM)3.68B
Analysts80
Price Target449.01 (11.33%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.29%
Min EPS beat(2)3.12%
Max EPS beat(2)3.45%
EPS beat(4)2
Avg EPS beat(4)-0.92%
Min EPS beat(4)-7.2%
Max EPS beat(4)3.45%
EPS beat(8)5
Avg EPS beat(8)-64.05%
EPS beat(12)7
Avg EPS beat(12)-42.39%
EPS beat(16)10
Avg EPS beat(16)-31.28%
Revenue beat(2)1
Avg Revenue beat(2)-0.58%
Min Revenue beat(2)-1.21%
Max Revenue beat(2)0.06%
Revenue beat(4)2
Avg Revenue beat(4)-0.82%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)2.68%
Revenue beat(8)3
Avg Revenue beat(8)-0.69%
Revenue beat(12)4
Avg Revenue beat(12)-0.78%
Revenue beat(16)7
Avg Revenue beat(16)-0.32%
PT rev (1m)5.57%
PT rev (3m)6.09%
EPS NQ rev (1m)-0.41%
EPS NQ rev (3m)0.16%
EPS NY rev (1m)0.1%
EPS NY rev (3m)1.78%
Revenue NQ rev (1m)-0.09%
Revenue NQ rev (3m)-0.34%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)0.02%
Valuation
Industry RankSector Rank
PE 25.9
Fwd PE 23.39
P/S 10.32
P/FCF 36.26
P/OCF 32.55
P/B 6.99
P/tB 7.66
EV/EBITDA 24.38
EPS(TTM)15.57
EY3.86%
EPS(NY)17.24
Fwd EY4.27%
FCF(TTM)11.12
FCFY2.76%
OCF(TTM)12.39
OCFY3.07%
SpS39.07
BVpS57.72
TBVpS52.66
PEG (NY)2.41
PEG (5Y)2.11
Graham Number142.2
Profitability
Industry RankSector Rank
ROA 14.78%
ROE 21.22%
ROCE 22.25%
ROIC 15.67%
ROICexc 22.65%
ROICexgc 25.38%
OM 38.7%
PM (TTM) 31.35%
GM 86.28%
FCFM 28.47%
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.53%
ROIC(5y)18.06%
ROICexc(3y)43.35%
ROICexc(5y)48.92%
ROICexgc(3y)62.02%
ROICexgc(5y)75.97%
ROCE(3y)24.89%
ROCE(5y)25.65%
ROICexgc growth 3Y-29.98%
ROICexgc growth 5Y-9.76%
ROICexc growth 3Y-22.64%
ROICexc growth 5Y-1.94%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
F-Score7
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 189.83%
Cap/Sales 3.25%
Interest Coverage 374.91
Cash Conversion 78.49%
Profit Quality 90.81%
Current Ratio 2.36
Quick Ratio 2
Altman-Z N/A
F-Score7
WACC8.68%
ROIC/WACC1.8
Cap/Depr(3y)171.61%
Cap/Depr(5y)187.83%
Cap/Sales(3y)3.11%
Cap/Sales(5y)3.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6248.28%
EPS 3Y7.33%
EPS 5Y12.27%
EPS Q2Q%26.38%
EPS Next Y10.74%
EPS Next 2Y11.49%
EPS Next 3Y10.83%
EPS Next 5Y11.8%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%9.55%
Revenue Next Year8.7%
Revenue Next 2Y9.21%
Revenue Next 3Y9.38%
Revenue Next 5Y9.15%
EBIT growth 1Y5.79%
EBIT growth 3Y16.47%
EBIT growth 5Y29.7%
EBIT Next Year824.9%
EBIT Next 3Y127.59%
EBIT Next 5Y70.14%
FCF growth 1Y-20.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.14%
OCF growth 3YN/A
OCF growth 5YN/A

VERTEX PHARMACEUTICALS INC / VX1.DE FAQ

What is the ChartMill fundamental rating of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to VX1.DE.


What is the valuation status for VX1 stock?

ChartMill assigns a valuation rating of 5 / 10 to VERTEX PHARMACEUTICALS INC (VX1.DE). This can be considered as Fairly Valued.


What is the profitability of VX1 stock?

VERTEX PHARMACEUTICALS INC (VX1.DE) has a profitability rating of 7 / 10.


How financially healthy is VERTEX PHARMACEUTICALS INC?

The financial health rating of VERTEX PHARMACEUTICALS INC (VX1.DE) is 6 / 10.


What is the earnings growth outlook for VERTEX PHARMACEUTICALS INC?

The Earnings per Share (EPS) of VERTEX PHARMACEUTICALS INC (VX1.DE) is expected to grow by 10.74% in the next year.